| References |
1. Bu W, Ren H, Deng Y, Del Mar N, Guley NM, Moore BM, Honig MG, Reiner A. Mild Traumatic Brain Injury Produces Neuron Loss That Can Be Rescued by Modulating Microglial Activation Using a CB2 Receptor Inverse Agonist. Front Neurosci. 2016 Oct 6;10:449. PubMed PMID: 27766068; PubMed Central PMCID: PMC5052277. 2. Presley C, Abidi A, Suryawanshi S, Mustafa S, Meibohm B, Moore BM. Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist. Pharmacol Res Perspect. 2015 Aug;3(4):e00159. doi: 10.1002/prp2.159. PubMed PMID: 26196013; PubMed Central PMCID: PMC4506688. 3. Reiner A, Heldt SA, Presley CS, Guley NH, Elberger AJ, Deng Y, D'Surney L, Rogers JT, Ferrell J, Bu W, Del Mar N, Honig MG, Gurley SN, Moore BM 2nd. Motor, visual and emotional deficits in mice after closed-head mild traumatic brain injury are alleviated by the novel CB2 inverse agonist SMM-189. Int J Mol Sci. 2014 Dec 31;16(1):758-87. doi: 10.3390/ijms16010758. PubMed PMID: 25561230; PubMed Central PMCID: PMC4307274. 4. Bhattacharjee H, Gurley SN, Moore BM 2nd. Design and synthesis of novel tri-aryl CB2 selective cannabinoid ligands. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1691-3. doi: 10.1016/j.bmcl.2009.01.100. PubMed PMID: 19230659. |
